title: Profile of gastrointestinal involvement in patients with systemic sclerosis.
abstract: Systemic sclerosis (SSc) is a chronic autoimmune connective tissue disease. Of the numerous organ manifestations, involvement of the upper and lower gastrointestinal tract (GIT) appears to be the most frequent with regard to the clinical symptoms. However, as the frequency and clinical relevance of GI involvement in patients with SSc are not known in detail, the German network of the systemic sclerosis (DNSS) has developed a detailed questionnaire to evaluate the extent and profile of gastrointestinal involvement in SSc patients. The multi-symptom questionnaire was used at baseline and after 1 year in registered patients of the DNSS. In addition, the results were compared with gastrointestinal disorders in patients with SSc and other rheumatic diseases, as well as with the medical history of the patients. In total, 90 patients were included in the study. The results of the study show that in reality, a much higher (nearly all) percentage of (98,9%) patients than expected suffer from GI-symptoms, regardless of the stage of their disease. Of these, meteorism (87,8%) was the most common followed by coughing/sore voice (77,8%), heartburn (daytime 68,9%, nighttime 53,3%), diarrhea (67,8%), stomach ache (68,9%) and nausea (61,1%). Although SSc patients were treated according to the respective recommendations, only limited improvements with regard to GI-symptoms could be achieved after 1 year of follow-up. In addition, the study revealed that the multi-symptom questionnaire is a useful tool to contribute to identify the gastrointestinal sequelae in systemic sclerosis.
authors.affiliation: Department of Rheumatology and Immunology, Kerckhoff-Clinic Bad Nauheim, Benekestr. 2- 8, 61231 Bad Nauheim, Germany. t.schmeiser@kerckhoff-klinik.de
authors.forename: T
authors.initials: T
authors.lastname: Schmeiser
authors.forename: P
authors.initials: P
authors.lastname: Saar
authors.forename: D
authors.initials: D
authors.lastname: Jin
authors.forename: M
authors.initials: M
authors.lastname: Noethe
authors.forename: A
authors.initials: A
authors.lastname: Müller
authors.forename: N
authors.initials: N
authors.lastname: Soydan
authors.forename: P D
authors.initials: PD
authors.lastname: Hardt
authors.forename: C
authors.initials: C
authors.lastname: Jaeger
authors.forename: O
authors.initials: O
authors.lastname: Distler
authors.forename: E
authors.initials: E
authors.lastname: Roeb
authors.forename: R G
authors.initials: RG
authors.lastname: Bretzel
authors.forename: U
authors.initials: U
authors.lastname: Müller-Ladner
mesh_terms: D016022:Case-Control Studies; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D005767:Gastrointestinal Diseases / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D005858:Germany / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D008947:Mixed Connective Tissue Disease / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D011379:Prognosis; D012042:Registries; D045743:Scleroderma, Diffuse / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D045745:Scleroderma, Limited / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D013997:Time Factors